You are here: Welcome to the MPKB » Welcome to the MPKB » Non-MP therapies » Non-MP antibacterials » High-dose antibiotic therapies
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
home:othertreatments:antibacterials:highdose [01.03.2012] – external edit 127.0.0.1home:othertreatments:antibacterials:highdose [09.14.2022] (current) – external edit 127.0.0.1
Line 23: Line 23:
 The absence of inflammation is undoubtedly one of the principal reasons why patients report feeling better on high-dose antibiotics. It is also why the guidelines for the Marshall Protocol recommend doses of antibiotics low enough to avoid the problem of uninterrupted immunosuppression. The presence of a sustained immunopathological response is evidence that the MP uses antibiotics in such a way that it does not suppress the immune system. The absence of inflammation is undoubtedly one of the principal reasons why patients report feeling better on high-dose antibiotics. It is also why the guidelines for the Marshall Protocol recommend doses of antibiotics low enough to avoid the problem of uninterrupted immunosuppression. The presence of a sustained immunopathological response is evidence that the MP uses antibiotics in such a way that it does not suppress the immune system.
  
-Note that formulations which keep antibiotic concentrations at artificially high concentrations such as extended-release minocycline(({{pubmed>long:17436826}})) have a similar immunosuppressive effect as high-dose antibiotics.+Note that formulations which keep antibiotic concentrations at artificially high concentrations such as extended-release minocycline(({{pmid>long:17436826}})) have a similar immunosuppressive effect as high-dose antibiotics.
 ==== Mechanisms of immunosuppression ==== ==== Mechanisms of immunosuppression ====
  
Line 33: Line 33:
 Moreover, pre-exposure to agents that selectively inhibit protein synthesis (30S or 50S subunit inhibitors) or DNA metabolism (DNA gyrase) mitigated subsequent tPMP-1 [an antimicrobial peptide] induced killing of an otherwise susceptible //S. aureus// strain in vitro. Moreover, pre-exposure to agents that selectively inhibit protein synthesis (30S or 50S subunit inhibitors) or DNA metabolism (DNA gyrase) mitigated subsequent tPMP-1 [an antimicrobial peptide] induced killing of an otherwise susceptible //S. aureus// strain in vitro.
  
- //**Michael Yeaman**// (({{pubmed>long:12615953}}))+ //**Michael Yeaman**// (({{pmid>long:12615953}}))
 </blockquote> </blockquote>
  
Line 41: Line 41:
 <blockquote>You can put a patient on [high-dose] antibiotics, and it may seem that the infection has disappeared. But in a few months, it reappears, and it is usually in an antibiotic-resistant form. <blockquote>You can put a patient on [high-dose] antibiotics, and it may seem that the infection has disappeared. But in a few months, it reappears, and it is usually in an antibiotic-resistant form.
  
- [[http://www.physorg.com/news114189450.html|Andre Levchenko]]</blockquote>+ [[https://www.physorg.com/news114189450.html|Andre Levchenko]]</blockquote>
  
   * **Activation of the PXR Nuclear Receptor** – Minocycline [[home:protocol:mp_antibiotics#activation_of_pregnane_x_nuclear_receptor|acting as a PXR agonist]] may be responsible for the palliation achieved when using high-dose minocycline, a treatment advocated by the Road Back Foundation.   * **Activation of the PXR Nuclear Receptor** – Minocycline [[home:protocol:mp_antibiotics#activation_of_pregnane_x_nuclear_receptor|acting as a PXR agonist]] may be responsible for the palliation achieved when using high-dose minocycline, a treatment advocated by the Road Back Foundation.
 ==== Curing disease by reducing inflammation? ==== ==== Curing disease by reducing inflammation? ====
  
-The immunosuppressive properties of antibiotics have been long known. Labro states that the tetracycline family of antibiotics – four of which are a part of the MP's guidelines – are desirable because they inhibit "detrimental" phagocyte activity.(({{pubmed>long:11023961}}))  +The immunosuppressive properties of antibiotics have been long known. Labro states that the tetracycline family of antibiotics – four of which are a part of the MP's guidelines – are desirable because they inhibit "detrimental" phagocyte activity.(({{pmid>long:11023961}}))  
  
 To that end, most researchers have assumed, consistent with the autoimmune theory of disease, that using antibiotics to reduce immune activity would improve disease.  To that end, most researchers have assumed, consistent with the autoimmune theory of disease, that using antibiotics to reduce immune activity would improve disease. 
  
-On the basis of this understanding, scientists have put forth work concluding that the tetracyclines are anywhere from somewhat to very effective against reactive arthritis,(({{pubmed>long:1670621}})) rheumatoid arthritis,(({{pubmed>long:7993000}})) scleroderma,(({{pubmed>long:9848358}})) and periodontal disease.(({{pubmed>long:2177499}})) Other diseases for which minocycline, a kind of tetracycline, has been proposed include stroke, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.(({{pubmed>long:18220943}})) (({{pubmed>long:18477398}})) +On the basis of this understanding, scientists have put forth work concluding that the tetracyclines are anywhere from somewhat to very effective against reactive arthritis,(({{pmid>long:1670621}})) rheumatoid arthritis,(({{pmid>long:7993000}})) scleroderma,(({{pmid>long:9848358}})) and periodontal disease.(({{pmid>long:2177499}})) Other diseases for which minocycline, a kind of tetracycline, has been proposed include stroke, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.(({{pmid>long:18220943}})) (({{pmid>long:18477398}})) 
  
-One study compared the use of hydroxychloroquine (Plaquenil) to minocycline in early seropositive rheumatoid arthritis patients.(({{pubmed>long:11665963}})) As a part of the study, one set of patients received 200mg of minocycline per day – four times as much as minocycline as an MP patient would ever take. That arm of the trial had a better outcome at the end of the study, but the absence of any supportive follow up research or longitudinal studies is revealing. +One study compared the use of hydroxychloroquine (Plaquenil) to minocycline in early seropositive rheumatoid arthritis patients.(({{pmid>long:11665963}})) As a part of the study, one set of patients received 200mg of minocycline per day – four times as much as minocycline as an MP patient would ever take. That arm of the trial had a better outcome at the end of the study, but the absence of any supportive follow up research or longitudinal studies is revealing. 
  
 Indeed, a number of studies have been able to demonstrate the "effectiveness" of a given antibiotic-based therapy on the basis of immunosuppression. Yet, these treatments do nothing to eradicate the bacteria causing the inflammation in the first place. This is true even of purportedly antibacterial treatments. Indeed, a number of studies have been able to demonstrate the "effectiveness" of a given antibiotic-based therapy on the basis of immunosuppression. Yet, these treatments do nothing to eradicate the bacteria causing the inflammation in the first place. This is true even of purportedly antibacterial treatments.
  
-One telling study looking at tetracycline's (the specific drug, not the family of drugs) "antibacterial" effects found that it temporarily reduced the appearance of acne, but without inhibiting the proliferation of //Propionibacterium acnes//, which has a role in causing acne.(({{pubmed>long:6237616}})) In her review, "Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or 'Immuno-Fairy Tales'?", Labro argues exactly this. +One telling study looking at tetracycline's (the specific drug, not the family of drugs) "antibacterial" effects found that it temporarily reduced the appearance of acne, but without inhibiting the proliferation of //Propionibacterium acnes//, which has a role in causing acne.(({{pmid>long:6237616}})) In her review, "Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or 'Immuno-Fairy Tales'?", Labro argues exactly this. 
  
 <blockquote>[There is a] lack of correlation between the drug dose regimen [for //Propionibacterium acnes//] and cutaneous bacterial counts. <blockquote>[There is a] lack of correlation between the drug dose regimen [for //Propionibacterium acnes//] and cutaneous bacterial counts.
  
-**//M.T. Labro//** (({{pubmed>long:11023961}}))</blockquote>+**//M.T. Labro//** (({{pmid>long:11023961}}))</blockquote>
  
-Earlier on in the paper, Labro concludes that when it comes to treating inflammatory diseases, immunosuppression is "recognized as the basis for antibiotic action."(({{pubmed>long:11023961}}))+Earlier on in the paper, Labro concludes that when it comes to treating inflammatory diseases, immunosuppression is "recognized as the basis for antibiotic action."(({{pmid>long:11023961}}))
  
    
Line 77: Line 77:
 ===== High-dose clarithomycin is ineffective ===== ===== High-dose clarithomycin is ineffective =====
  
-In a 2006 trial appearing in //BMJ// (nicknamed the CLARICOL trial), 13,702 patients with a history of myocardial infarction or angina pectoria (chest pain) were given two weeks' treatment with clarithromycin 500 mg/day or matching placebo. Mortality was significantly higher in the clarithromycin arm as a result of significantly higher cardiovascular mortality. The authors concluded: "Short term clarithromycin in patients with stable coronary heart disease may cause significantly higher cardiovascular mortality. The long term safety of clarithromycin in patients with stable ischaemic heart disease should be examined."(({{pubmed>long:16339220}}))+In a 2006 trial appearing in //BMJ// (nicknamed the CLARICOL trial), 13,702 patients with a history of myocardial infarction or angina pectoria (chest pain) were given two weeks' treatment with clarithromycin 500 mg/day or matching placebo. Mortality was significantly higher in the clarithromycin arm as a result of significantly higher cardiovascular mortality. The authors concluded: "Short term clarithromycin in patients with stable coronary heart disease may cause significantly higher cardiovascular mortality. The long term safety of clarithromycin in patients with stable ischaemic heart disease should be examined."(({{pmid>long:16339220}}))
  
 These results are consistent with the explanation that immunosuppressive therapies exacerbate inflammatory diseases. These results are consistent with the explanation that immunosuppressive therapies exacerbate inflammatory diseases.
Line 86: Line 86:
  
  
-Fallon //et al// treated patients diagnosed with Lyme disease with intravenous ceftriaxone (Rocephin) for a period of 24 weeks.(({{pubmed>long:17928580}})) While patients in the experimental arm of the trial experienced improvement in pain, fatigue, and physical functioning, these changes were short-lived. According to Fallon: +Fallon //et al// treated patients diagnosed with Lyme disease with intravenous ceftriaxone (Rocephin) for a period of 24 weeks.(({{pmid>long:17928580}})) While patients in the experimental arm of the trial experienced improvement in pain, fatigue, and physical functioning, these changes were short-lived. According to Fallon: 
  
 <blockquote>The improvement... was not sustained to week 24....  10 weeks of IV ceftriaxone followed by 14 weeks of no antibiotic is not an effective strategy. <blockquote>The improvement... was not sustained to week 24....  10 weeks of IV ceftriaxone followed by 14 weeks of no antibiotic is not an effective strategy.
  
-//**B.A. Fallon,** et al.// (({{pubmed>long:17928580}}))</blockquote>+//**B.A. Fallon,** et al.// (({{pmid>long:17928580}}))</blockquote>
  
 The study also revealed that more than one quarter of antibiotic-treated patients had significant adverse effects necessitating treatment termination. The study also revealed that more than one quarter of antibiotic-treated patients had significant adverse effects necessitating treatment termination.
Line 98: Line 98:
 <blockquote>140 g of ceftriaxone should have eliminated any spirochetes present in these patients.... In sum, this is now the fourth randomized blinded trial of prolonged antimicrobial therapy in patients previously treated for Lyme disease. Like the other three, it clearly demonstrates the absence of any lasting improvement in cognitive function. Given the considerable risk of serious adverse events from prolonged [high-dose] antibiotic treatment, it is time to look elsewhere for an effective management strategy to help patients with persistent cognitive symptoms after treatment for Lyme disease. Clearly, enough is enough. <blockquote>140 g of ceftriaxone should have eliminated any spirochetes present in these patients.... In sum, this is now the fourth randomized blinded trial of prolonged antimicrobial therapy in patients previously treated for Lyme disease. Like the other three, it clearly demonstrates the absence of any lasting improvement in cognitive function. Given the considerable risk of serious adverse events from prolonged [high-dose] antibiotic treatment, it is time to look elsewhere for an effective management strategy to help patients with persistent cognitive symptoms after treatment for Lyme disease. Clearly, enough is enough.
  
-//**John J. Halperin MD**// (({{pubmed>long:17928578}}))</blockquote>+//**John J. Halperin MD**// (({{pmid>long:17928578}}))</blockquote>
  
  
-Other controlled trials have found no improvement in treatment outcome when the length of the study was extended.(({{pubmed>long:17587070}}))+Other controlled trials have found no improvement in treatment outcome when the length of the study was extended.(({{pmid>long:17587070}}))
  
  
Line 114: Line 114:
 <blockquote>Under the care of one of the few treating doctors in Canada, I did six more years of high-dose antibiotics. I did experience immunopathology in response to taking many of them, but my symptoms never came close to resolving. Sometimes I would seem to reach a plateau, but then I would inevitably relapse. It seemed like the antibiotics were helping me somewhat, but taking them at high doses was like taking three steps forward and two steps backwards. When I had IV rocephin for three months, I started to feel like I was making no progress at all - it was three steps forward, three steps backwards. I think this pattern might have gone on forever if I hadn’t found the Marshall Protocol. <blockquote>Under the care of one of the few treating doctors in Canada, I did six more years of high-dose antibiotics. I did experience immunopathology in response to taking many of them, but my symptoms never came close to resolving. Sometimes I would seem to reach a plateau, but then I would inevitably relapse. It seemed like the antibiotics were helping me somewhat, but taking them at high doses was like taking three steps forward and two steps backwards. When I had IV rocephin for three months, I started to feel like I was making no progress at all - it was three steps forward, three steps backwards. I think this pattern might have gone on forever if I hadn’t found the Marshall Protocol.
  
-//**Ken L.**, [[http://bacteriality.com/2008/03/31/interview19/|Bacteriality inteview]]//</blockquote>+//**Ken L.**, [[https://bacteriality.com/2008/03/31/interview19/|Bacteriality inteview]]//</blockquote>
  
  
Line 122: Line 122:
 ===== Read more ===== ===== Read more =====
  
-  * [[http://www.medscape.com/viewarticle/586226|Chronic Lyme Disease and the "Axis of Evil"]]  – discussion of the debate surrounding Lyme, one exacerbated by the fact that high-dose antibiotics are ineffective for the disease; source: Medscape (registration required)+  * [[https://www.medscape.com/viewarticle/586226|Chronic Lyme Disease and the "Axis of Evil"]]  – discussion of the debate surrounding Lyme, one exacerbated by the fact that high-dose antibiotics are ineffective for the disease; source: Medscape (registration required)
  
  
-{{tag>antibiotics}}+{{tag>Other_medication}}
  
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
Line 141: Line 142:
 Antibiotics have been used effectively as a means to treat bacterial infections in humans and animals for over half a century. However, through their use, lasting alterations are being made to a mutualistic relationship that has taken millennia to evolve: the relationship between the host and its microbiota. Host–microbiota interactions are dynamic; therefore, changes in the microbiota as a consequence of antibiotic treatment can result in the dysregulation of host immune homeostasis and an increased susceptibility to disease. A better understanding of both the changes in the microbiota as a result of antibiotic treatment and the consequential changes in host immune homeostasis is imperative, so that these effects can be mitigated. Antibiotics have been used effectively as a means to treat bacterial infections in humans and animals for over half a century. However, through their use, lasting alterations are being made to a mutualistic relationship that has taken millennia to evolve: the relationship between the host and its microbiota. Host–microbiota interactions are dynamic; therefore, changes in the microbiota as a consequence of antibiotic treatment can result in the dysregulation of host immune homeostasis and an increased susceptibility to disease. A better understanding of both the changes in the microbiota as a result of antibiotic treatment and the consequential changes in host immune homeostasis is imperative, so that these effects can be mitigated.
 </blockquote> </blockquote>
-===== References =====+===== References =====</nodisp> 
home/othertreatments/antibacterials/highdose.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.